BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters
Phase 2
Completed
- Conditions
- Pregnancy, Unplanned
- Interventions
- Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)Drug: SH D01155E
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 29
- Registration Number
- NCT00318799
- Locations
- 🇳🇱
Dinox B.V., Groningen, Netherlands
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Phase 4
Completed
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Drug: Betaferon/BetaseronDrug: Rebif
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT00317941
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT00313248
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3
Withdrawn
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Bayer
- Registration Number
- NCT00313976
Magnevist® Injection-enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis of the Renal Arteries
Phase 3
Completed
- Conditions
- Renal Artery Stenosis
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116
- Registration Number
- NCT00310557
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Phase 2
Completed
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 73
- Registration Number
- NCT00310544
3-year Study of Menostar Versus Evista to Prevent Osteoporosis in Post-menopausal Women
Phase 3
Completed
- Conditions
- Osteopenia
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT00310531
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 71
- Registration Number
- NCT00310596
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches
Phase 3
Completed
- Conditions
- Cardiovascular Abnormalities
- Interventions
- First Posted Date
- 2006-04-04
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 123
- Registration Number
- NCT00310609
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 126
- Registration Number
- NCT00309075
© Copyright 2025. All Rights Reserved by MedPath